SEARCH:   Advanced

Blood, 15 January 2004, Vol. 103, No. 2, pp. 428-434. Prepublished online as a Blood First Edition Paper on September 11, 2003; DOI 10.1182/blood-2003-05-1406. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-05-1406v1 103/2/428    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Faulkner, R. D. Articles by Russell, N. H. Search for Related Content PubMed PubMed Citation Articles by Faulkner, R. D. Articles by Russell, N. H. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients Rowena D. Faulkner, Charles Craddock, Jennifer L. Byrne, Prem Mahendra, Andrew P. Haynes, Hugh G. Prentice, Michael Potter, Antonio Pagliuca, Aloysius Ho, Stephen Devereux, Grant McQuaker, Ghulam Mufti, John Liu Yin, and Nigel H. Russell From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom. We report the outcomes of reduced-intensity allogeneic stem cell transplantation using BEAM-alemtuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg/d on days –5 to –1) in 6 United Kingdom transplant centers. Sixty-five patients with lymphoproliferative diseases underwent sibling (n = 57) or matched unrelated donor (n = 8) transplantation. Sustained donor engraftment occurred in 60 (97%) of 62 patients. Of the 56 patients undergoing chimerism studies, 35 (63%) had full donor chimerism. Overall, 73% were in complete remission (CR) after transplantation. At a median follow-up of 1.4 years (range, 0.1-5.6 years), 37 remain alive and in CR. Acute graft-versus-host disease (GVHD) occurred in 11 (17%) of 64, grades I-II only. Estimated 1-year transplantation-related mortality (TRM) was 8% for patients undergoing first transplantation but was significantly worse for those who had previously undergone autologous transplantation. Six patients relapsed (estimated 2-year relapse risk, 20%). Histologic diagnosis (mantle cell lymphoma and high-grade non-Hodgkin lymphoma) and age at transplantation (> 46 years) were significantly associated with higher relapse risk and worse event-free survival. Relapse did not occur in any patient who developed acute or chronic GVHD. This study demonstrates that reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases using a BEAM-alemtuzumab preparative regimen is associated with sustained donor engraftment, a high response rate, minimal toxicity, and a low incidence of GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. P. Robinson, A. Sureda, C. Canals, N. Russell, D. Caballero, A. Bacigalupo, A. Iriondo, G. Cook, A. Pettitt, G. Socie, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome Haematologica, February 1, 2009; 94(2): 230 - 238. [Abstract] [Full Text] [PDF] K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al. Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2009; 27(3): 426 - 432. [Abstract] [Full Text] [PDF] A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., January 20, 2008; 26(3): 455 - 462. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood, January 1, 2008; 111(1): 446 - 452. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF] L. Farina and P. Corradini Current role of allogeneic stem cell transplantation in follicular lymphoma Haematologica, May 1, 2007; 92(5): 580 - 582. [Full Text] [PDF] S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) Clin. Cancer Res., December 1, 2006; 12(23): 7174 - 7179. [Abstract] [Full Text] [PDF] I. F. Khouri Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Hematology, January 1, 2006; 2006(1): 390 - 397. [Abstract] [Full Text] [PDF] N. L. Bartlett Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy Hematology, January 1, 2005; 2005(1): 245 - 251. [Abstract] [Full Text] [PDF] E. Morris, K. Thomson, C. Craddock, P. Mahendra, D. Milligan, G. Cook, G. M. Smith, A. Parker, S. Schey, R. Chopra, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma Blood, December 15, 2004; 104(13): 3865 - 3871. [Abstract] [Full Text] [PDF] M. B. Maris, B. M. Sandmaier, B. E. Storer, T. Chauncey, M. J. Stuart, R. T. Maziarz, E. Agura, A. A. Langston, M. Pulsipher, R. Storb, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma Blood, December 1, 2004; 104(12): 3535 - 3542. [Abstract] [Full Text] [PDF] J. N. Winter, R. D. Gascoyne, and K. Van Besien Low-Grade Lymphoma Hematology, January 1, 2004; 2004(1): 203 - 220. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020